Spero Therapeutics (SPRO) Price to Sales (2017 - 2026)

Spero Therapeutics (SPRO) has reported Price to Sales for 10 consecutive years, with 525.06 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Price to Sales rose 7562.94% year-over-year to 525.06; the trailing twelve-month figure through Jun 2026 stood at 2.73 (down 18.49% YoY), and the FY2025 full-year result was 1.97, up 67.89% from the prior year.
• Price to Sales advanced to 525.06 in Q1 2026 per SPRO's latest filing, from 3.18 in the prior quarter.
• Across five years, Price to Sales topped out at 525.06 in Q1 2026 and bottomed at 1.06 in Q4 2023.
• Historically, Price to Sales has averaged 50.32 across 5 years, with a median of 10.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Price to Sales slumped 99.27% in 2022, then jumped 7562.94% in 2026.
• Over 5 years, Price to Sales stood at 1.37 in 2022, then dropped by 22.68% to 1.06 in 2023, then jumped by 252.73% to 3.74 in 2024, then slipped by 14.84% to 3.18 in 2025, then soared by 16396.11% to 525.06 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 525.06, 3.18, and 19.45 for Q1 2026, Q4 2025, and Q3 2025 respectively.